Methylprednisolone

• Evaluation of the postoperative analgesic efficacy of erector spinae plane block in lumbar spinal surgery: a prospective randomized double-b… Recruiting
  2023-504204-28-00 Phase IV 1 country CHU De Liege
• Treatment of Menière's disease with intratympanic methylprednisolone (PREDMEN trial) Recruiting
  2023-503340-13-00 Phase III 1 country Leiden University Medical Center
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting
  2022-502851-79-00 Phase III 19 countries Argenx
• The iCaD Study Recruiting
  2022-503026-12-00 Phase III 1 country Odense University Hospital
• CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting
  2023-504999-25-00 Phase III 12 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
• Desensitisation with imlifidase prior to kidney transplant in highly sensitised children Recruiting
  2022-500230-28-00 Phase II 4 countries Hansa Biopharma AB
• STEAROID TREATMENT IN PATIENTS WITH HEART ATTACK Recruiting
  2022-500762-10-00 Phase II 1 country Rigshospitalet
• A clinical study in 3 parts with a microdystrophin (called GNT0004), a new gene therapy in boys with Duchenne disease who can still walk. Th… Recruiting
  2023-505187-11-00 Phase I (FiH) 3 countries Genethon
• Evaluation of Lymphadenectomy and Chemotherapy TIP (paclitaxel, ifosfamide and cisplatin) on Inguinal Lymph Nodes in Squamous Cell Carcinoma… Recruiting
  2024-512827-36-00 Phase II 1 country Unicancer
• A Phase 1/2 Study with Ascending Dose in order to Evaluate the Safety and Effects on Progranulin Levels of investigational product under cod… Ended
  2022-502942-29-01 Phase I/II 2 countries Prevail Therapeutics Inc.
• INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru… Ended
  2022-502168-19-00 Phase II 4 countries Incyte Corp.
• Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to expre… Ended
  2024-515467-66-00 Phase II 1 country Fundacio Sant Joan De Deu
• Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases Ended
  2023-509555-13-00 Phase I 1 country Tg Therapeutics Inc.
• A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S… Ended
  2022-501622-37-00 Phase III 6 countries Celltrion Inc.
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended
  2023-506986-74-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
• The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa… Ended
  2024-516868-28-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended
  2023-506515-18-00 Phase III 11 countries F. Hoffmann-La Roche AG
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended
  2023-506467-34-00 Phase III 10 countries F. Hoffmann-La Roche AG
• PACIFICA: A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thro… Ended
  2024-515953-52-00 Phase III 8 countries Sobi Inc.
• Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab. Ended
  2023-510248-19-00 Phase III 4 countries AstraZeneca AB
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Rela… Ended
  2023-507313-94-00 Phase II 2 countries F. Hoffmann-La Roche AG
• A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis Ended
  2023-506429-13-00 Phase III 7 countries F. Hoffmann-La Roche AG
• A dose finding study of LY3884961 in patients with Gaucher disease Halted
  2022-500281-10-02 Phase I/II 2 countries Prevail Therapeutics Inc.
• VAsopressin and STeroids in addition to Adrenaline in cardiac arrest - a randomized clinical trial. VAST-A Halted
  2025-521283-35-00 Phase III 1 country Tiohundra AB

Showing 25–48 of 62 trials